Evidence map›Paper›PMID 35336942›Full record

ArticleViruses2022

Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression.

Mariano Carossino, Devin Kenney, Aoife K O'Connell, Paige Montanaro, Anna E Tseng, Hans P Gertje, Kyle A Grosz, Maria Ericsson, Bertrand R Huber, Susanna A Kurnick and 11 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. A multimodaliScience · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. SARS-CoV-2-International journal of microbiology · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Mariano CarossinoLouisiana Animal Disease Diagnostic Laboratory (LADDL), Louisiana State University, Baton Rouge, LA 61329, USA.ORCID 0000-0003-3864-5915
Devin KenneyNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Aoife K O'ConnellNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Paige MontanaroNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Anna E TsengNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Hans P GertjeNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Kyle A GroszNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Maria EricssonElectron Microscopy Core Facility, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-4563-3683
Bertrand R HuberDepartment of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
Susanna A KurnickNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Saravanan SubramaniamDepartment of Medicine, Pulmonary Center, Boston University School of Medicine, Boston, MA 02118, USA.ORCID 0000-0002-0194-5044
Thomas A KirklandPromega Biosciences, LLC, San Luis Obispo, CA 93401, USA.ORCID 0000-0003-0859-5785
Joel R WalkerPromega Biosciences, LLC, San Luis Obispo, CA 93401, USA.
Kevin P FrancisPerkin Elmer, Hopkinton, MA 01748, USA.
Alexander D KloseInVivo Analytics Inc., New York, NY 10023, USA.
Neal ParagasInVivo Analytics Inc., New York, NY 10023, USA.
Markus BosmannNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.ORCID 0000-0003-2773-1033
Mohsan SaeedNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.
Udeni B R BalasuriyaLouisiana Animal Disease Diagnostic Laboratory (LADDL), Louisiana State University, Baton Rouge, LA 61329, USA.ORCID 0000-0003-0609-678X
Florian DouamNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.ORCID 0000-0002-4791-6767
Nicholas A CrosslandNational Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA.ORCID 0000-0003-3873-9188
Boston University · USLouisiana State University · USPromega (United States) · USHarvard University · USInVivo Analytics (United States) · USPerkinElmer (United States) · USUniversity of Washington · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and DiseaseR21ES032882 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DOUAM, FLORIAN, SCHLEZINGER, JENNIFER J · 2021 to 2022
$445k
Vectra Polaris Quantitative Pathology Imaging SystemS10OD030269 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2021 to 2021
$402k
Characterization of a human-specific positive regulator of flavivirus infectionK22AI144050 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DOUAM, FLORIAN · 2021 to 2023
$344k
Ventana Discovery Ultra Research Autostainer: an Ex+ Core serviceS10OD026983 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2019 to 2019
$207k
Louisiana State University PG002165NCATS NIH HHS UL1 TR001430NIH HHS 1UL1TR001430NIH HHS K22 AI144050NIH HHS R21 ES032882NIH HHS S10 OD026983NIH HHS S10OD026983NIH HHS S10 OD030269NIH HHS S10OD030269
6 · The paper itself

Abstract

Animal models recapitulating COVID-19 are critical to enhance our understanding of SARS-CoV-2 pathogenesis. Intranasally inoculated transgenic mice expressing human angiotensin-converting enzyme 2 under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection. We evaluated the clinical and virological dynamics of SARS-CoV-2 using two intranasal doses (10

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2Animalsgamma-GlobulinsHumansKeratin-18MelphalanMiceMice, TransgenicViral TropismACE2 protein, humanAngiotensin-Converting Enzyme 2gamma-GlobulinsKeratin-18Melphalancomparative pathologyimmunohistochemistryin situ hybridizationin vivo imagingtranslational animal modeltransmission electron microscopyviral pathogenesis

Identifiers

PMID35336942
PMCPMC8955233
OpenAlexW4220845085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.